Bristol-Myers Squibb Company

BMY · Healthcare · · USD

66.82 USD

0.00 (-1.87%)

● Updated 2026-09-07 18:34 Saudi Time ↻ Refresh

Short-term Mid-term Long-term

Fahodi Score BUY Mid-term (Position)

/ 100

Technical 75

Trend & RS 97

Momentum 72

Fundamental 67

Macro 64

Liquidity 44

Component	Score	Weight
Technical	75.0	20%
Trend & RS	96.8	30%
Momentum	71.8	15%
Fundamental	66.7	10%
Macro	64.4	20%
Liquidity	43.7	5%

Trade Setup

Entry	66.82
Stop Loss	63.80 (4.5%)
Target 1 (1:1)	69.84 (+4.5%)
Target 2 (2:1)	72.86 (+9.0%)

ATR(14)	1.51 (2.3%)
Risk per Share	3.02
Reward:Risk	2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor	Score	Z
Value	59.6	+0.39
Momentum	71.8	+0.87
Quality	62.4	+0.50
Composite	64.6

Quality Scores

Piotroski F-Score 6 /9 — Average

✓ ✓ ✗ ✗ ✗ ✓ ✓ ✓ ✓

1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover

Altman Z-Score Insufficient Data

Valuation vs Peers Fair Value

Metric	Stock	Sector	vs Peers
P/E Ratio	14.7	22.0	-33% below
P/B Ratio	6.1	4.0	Above
Dividend Yield	3.8%	1.5%	Above avg

Comparing against Healthcare median multiples.

Intrinsic Value (DCF) Fairly Valued

Intrinsic Value

65.69

Market Price

66.82

Upside

-1.7%

Margin of Safety	-1.7%
Stage 1 PV (5yr FCF)	33,859,409,261
Terminal Value PV	100,324,378,636
Total Enterprise Value	134,183,787,897

Assumptions

Base FCF	7,419,139,260
Growth Rate (5yr)	5.7%
Terminal Growth	2.5%
Discount Rate (WACC)	9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%

Recommended Size

49.54%

Full Kelly

24.77%

Half Kelly

5.0%

Max Cap (Moderate)

Kelly inputs derived from quant score 76/100. Estimated win rate 63%, avg win 9.6%, avg loss 3.5%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

Bullish Signals

Bearish Signals

56.57

RSI(14)

1.2784

MACD

Relative Strength (RS) IMPROVING

/ 99

RS Rating

✓ O'Neil PASS (≥80)

RS vs SPY	↑ RISING (+13.3% vs SPY 3M)
RS vs Sector	OUTPERFORMING (Healthcare)
RS New High	No (8d since high)
Sector Outperformance	+10.2% (3M)

RS Line — stock / SPY (90 bars)

← older newer →

RS vs SPY 50-day SMA of RS

IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

Indicator	Value	Signal
Rsi	56.57	NEUTRAL
Macd	1.2784	BEARISH
Ma Cross	62.85 / 57.3	GOLDEN CROSS
Trend Short		ABOVE SMA50
Trend Long		ABOVE SMA200
Bollinger		MIDDLE
Volume	0.59x	NORMAL

Key Levels

Level	Price
52-Week High	68.64
Bollinger Upper	69.18
SMA(200)	57.3
SMA(50)	62.85
SMA(20)	66.2
Current Price	66.82
Bollinger Lower	63.22
52-Week Low	42.52
ATR(14)	1.51

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence

100%

Acc: 0.0 | Dist: 0.0 | Markup: 2.0 | Markdown: 0.0

Volume Spread Analysis (last 5 bars)

Date	Signal	Vol	Description
2026-08-31	Normal	1.56x	Normal bar — no special VSA pattern
2026-09-01	Normal	0.85x	Normal bar — no special VSA pattern
2026-09-02	Normal	0.96x	Normal bar — no special VSA pattern
2026-09-03	Normal	0.77x	Normal bar — no special VSA pattern
2026-09-04	Normal	0.59x	Normal bar — no special VSA pattern

Ichimoku Cloud BULLISH

Line	Value	Status
Tenkan-sen (9)	67.07	Above Kijun
Kijun-sen (26)	65.82	Base line
Senkou A	66.45	Leading span A
Senkou B	61.40	Leading span B
Cloud	61.40 – 66.45	Bullish (Green)
Price vs Cloud	66.82	Above Cloud
Chikou Span	65.31	Bullish
Alignment Score	4/4	BULLISH